Welcome to the e-CCO Library!

P360 Safety and clinical efficacy of double switch from originator infliximab to biosimilars CT-P13 and SB2 in patients with inflammatory bowel diseases (SCESICS): A multicentre study
Year: 2020
Source:

ECCO'20 Vienna

Authors:

S. Mazza1, A. Fascì1, V. Casini2, C. Ricci3, F. Munari3, L. Pirola4, C. Girelli5, G. Lupinacci6, L. Pastorelli7, F. Cavallaro7, N. Piazza O’Sed7, L. Ferraris8, A. Colucci8, A. Amato9, V. Maurizio1,10, G. Fiorino11, F. Caprioli1,10

Created: Thursday, 30 January 2020, 10:12 AM
P360: A randomised, assessor-blinded, multicentre trial comparing the efficacy, safety, and tolerability of a new tailored dosing regimen to day-before dosing regimen of colon cleansing agent used before colonoscopy
Year: 2016
Source: ECCO '16 Amsterdam
Authors:

R. Kiesslich*1, C. Angelin2, K. Raymond2, W. Man A Hing3, J. Masure3, M. Stoltenberg2

Created: Friday, 22 February 2019, 9:49 AM
P360: Aggressive Inflammatory Bowel Disease is associated to Hermansky-Pudlak Syndrome: Characterization of a Puerto Rican Cohort
Year: 2021
Source: ECCO'21 Virtual
Authors: Marrero Torres, R.(1);Coste-Sibilia, S.(1);Nieves-Jimenez, H.(1);Torres, G.(1);Rivera, E.(2);Torres, E.A.(1);
Created: Wednesday, 2 June 2021, 4:12 PM
P360: Inflammatory microheterogeneity in ulcerative colitis: implications for microscopic assessment of disease activity
Year: 2019
Source:

ECCO '19 Copenhagen

Authors:

N. Harpaz1,2, S. Ballentine1, B. E. Sands2, J-F. Colombel2, H. M. Ko*1,2

Created: Friday, 22 February 2019, 9:41 AM
P360: Role of intestinal ultrasound scores in the diagnosis of post-operative recurrence in Crohn's disease
Year: 2023
Source: ECCO’23 Copenhagen
Authors: Amor Costa, C.(1)*;Suárez Ferrer , C.(1);Poza Cordón, J.(1);Yebra Carmona , J.(1);Rueda García , J.L.(1);Sánchez Azofra , M.(1);Martín Arranz, E.(1);González Díaz, I.(1);Amiama Roig, C.(1);Martín Arranz, M.D.(1);
Created: Friday, 14 July 2023, 11:05 AM
P360: The correlation between ophthalmological posterior segment findings and disease severity in patients with inflammatory bowel disease
Year: 2022
Source: ECCO'22
Authors: Mitrovic, M.(1);Jeremić, M.(2);Zlatković, D.(1);Pantelić, M.(1);Vrinić-Kalem, D.(1);
Created: Friday, 11 February 2022, 3:52 PM
P360: Trough levels and antibodies to ustekinumab are not correlated to response to ustekinumab treatment in Crohn's disease patients
Year: 2017
Source: ECCO '17 Barcelona
Authors:

Claire P.*1, Severine B.2, Nicolas D.3, Maria N.4, Pierre D.4, Julien B.4, Romain G.4, Medina B.4, Myriam L.2, Benjamin P.4

Created: Wednesday, 20 February 2019, 10:36 AM
P360: TrueColours ulcerative colitis (TCUC): Will patients with UC complete digital questionnaires in real-time?
Year: 2018
Source: ECCO '18 Vienna
Authors:

A. Walsh1*, M. Peters2, C. Hinds3, A. Kormilitzin4, V. Sexton5, P. Seeva1, O. Brain1, S. Keshav1, H. Uhlig1, A. Simmons6, J. Geddes5, G. Goodwin5, G. Collins7, S. Travis1

Created: Thursday, 21 February 2019, 9:14 AM
P361: Adherence to faecal calprotectin test in patients with inflammatory bowel disease
Year: 2016
Source: ECCO '16 Amsterdam
Authors:

C. Maréchal*1, I. Gastin2, C. Baumann2, B. Dirrenberger1, J.-L. Gueant2, L. Peyrin-Biroulet1

Created: Friday, 22 February 2019, 9:49 AM
P361: Laboratory criteria of infliximab therapy inefficiency in children with IBD
Year: 2019
Source:

ECCO '19 Copenhagen

Authors:

A. Potapov*1, T. Radigina2, S. Petrichuk2, D. Gerasimova2, A. Illarionov1,3, A. Anushenko1, T. Erlikh-Fox4

Created: Friday, 22 February 2019, 9:41 AM
P361: Machine learning models at week 6 of vedolizumab therapy for ulcerative colitis can predict week 52 corticosteroid free endoscopic remission
Year: 2017
Source: ECCO '17 Barcelona
Authors:

Waljee A.1, Liu B.2, Sauder K.1, Zhu J.2, Govani S.1, Stidham R.W.1, Higgins P.D.*3

Created: Wednesday, 20 February 2019, 10:36 AM
P361: No increased postoperative risk of venous thromboembolism in patients with Ulcerative Colitis undergoing colectomy after tofacitinib exposure
Year: 2021
Source: ECCO'21 Virtual
Authors: De Greef, I.(1);Verstockt, B.(1);Bislenghi, G.(2);Terrasson, I.(2);Sabino, J.(1);Ferrante, M.(1);D’Hoore, A.(2);Vermeire, S.(1);
Created: Wednesday, 2 June 2021, 4:12 PM
P361: Patterns of use and durability of initial and sequential biological agents in a large Paediatric inflammatory bowel disease observational cohort
Year: 2018
Source: ECCO '18 Vienna
Authors:

J. Kaplan1,2*, C. Liu3, E. King3, J. Bass4, A. Patel5, G. Tomer6, J. Tung7, J. Pratt3, S. Chen3, T. Lissoos8, R. Colletti9, ImproveCareNow Network

Created: Thursday, 21 February 2019, 9:14 AM
P361: PREPARE-IBD: Physician Responses to disease Flares and Patient Adaptation in Relation to Events in Inflammatory Bowel Disease during the COVID-19 pandemic: A multicentre cohort analysis
Year: 2022
Source: ECCO'22
Authors: Saifuddin, A.(1);Kent, A.(2);Mehta, S.(3);Hicks, L.(4);Gonzalez, H.(5);Segal, J.(4);Brooks, M.(6);Subramanian, S.(7);Bhala, N.(8);Conley, T.(7);Patel, K.(9);Lamb, C.(10);Walker, G.(11);Kennedy, N.(12);Sebastian, S.(5);
Created: Friday, 11 February 2022, 3:52 PM
P361: Risk of persistent gastrointestinal inflammation after treatment with immune checkpoint inhibitors
Year: 2023
Source: ECCO’23 Copenhagen
Authors: Jeay, M.(1)*;Carbonnel, F.(1);Robert, C.(2);Bellanger, C.(1);Meyer, A.(1);
Created: Friday, 14 July 2023, 11:05 AM
P362 Prospective study of phArmaCokinetics of InFliximab during induction in patients with Crohn’s disease and ulcerative colitis (PACIFIC)
Year: 2020
Source:

ECCO'20 Vienna

Authors:

C. Liefferinckx1, P. Bossuyt2, D. Thomas3, J.F. Rahier4, E. Louis5, F. Baert6, P. Dewint7,8, L. Pouillon2, G. Lambrecht9, S. Vermeire10, D. Franchimont1, of Belgian Inflammatory Bowel Disease Research and Development (BIRD)

Created: Thursday, 30 January 2020, 10:12 AM
P362: Anti-virus treatment against CMV in patients with ulcerative colitis by the PCR monitoring for mucosal CMV-DNA
Year: 2016
Source: ECCO '16 Amsterdam
Authors:

M. Tanaka*, T. Takagi, Y. Toyokawa, Y. Hotta, K. Uchiyama, Y. Naito, Y. Itoh

Created: Friday, 22 February 2019, 9:49 AM
P362: Faecal calprotectin is an early predictor of endoscopic response and histological remission after the start of vedolizumab
Year: 2019
Source:

ECCO '19 Copenhagen

Authors:

R. W. M. Pauwels*1, A. C. de Vries1, J. C. Goet1, N. S. Erler2, C. J. van der Woude1

Created: Friday, 22 February 2019, 9:41 AM
P362: Influence of HLA DQA1*05 genotype in patients with inflammatory bowel disease and Anti-TNF treatment with proactive therapeutic drug monitoring.
Year: 2022
Source: ECCO'22
Authors: Fuentes-Valenzuela, E.(1);García-Alonso , F.J.(1); Maroto-Martín , C.(1);Juan-Casamayor , L.(1);Garrote Adrados , J.A.(2);Almendros Muñoz , R.(3);de Prado , Á.(1);Marinero , M.Á.(1);Calleja Carbajosa , R.(1);Vara Castrodeza, A.(4);Barrio , J.(1);
Created: Friday, 11 February 2022, 3:52 PM